<ul><li>WuXi AppTec, a leading Chinese contract research organization, plans to sell its Advanced Therapies unit.</li><li>The decision is a response to increasing US restrictions on Chinese biotech firms.</li><li>The unit specializes in gene and cell therapy manufacturing, biopharma development services, and global collaboration.</li><li>The sale raises questions about WuXi's long-term strategy and highlights challenges in the biotech sector.</li></ul>

China’s WuXi Plans Sale of Advanced Therapies Unit Amid Tightening US Restrictions

Discover more